Interview with CEO Cristiana Vignoli on Rassegna Business: strategic insights on regenerative medicine in spinal cord injuries

Feb 26, 2026 | News, Press Releases

Regenerative medicine is currently one of the main areas of research in neurological diseases, driven by increasing interest in the immunological mechanisms involved in nervous tissue repair. Within this context, research conducted by the Hemera team has highlighted...

Reprogrammed Macrophage Research REMaST® presented at International Symposium in Houston

Feb 20, 2026 | Events, News

At the 2026 International Cancer Neuroscience Symposium in Houston (USA) the prestigious scientific forum organized by MD Anderson Cancer Center and Advanced Portfolio, Professor Francesco Bifari, co-founder and Director of Therapy Development at Hemera, was invited...

Hemera featured on the cover of Immunity: full version of the REMaST® study published

Feb 11, 2026 | News, Press Releases

Immunity by Cell Press dedicates the cover of Volume 59, Issue 2,10 February 2026 to our study reporting the preclinical data underpinning the REMaST® therapeutic platform. Cristiana Vignoli, CEO of Hemera, stated:“The cover of Immunity confirms the value of Italian...

TG3 Leonardo features an in-depth report on REMaST® and macrophage-based research for nervous system regeneration

Jan 27, 2026 | News, Press Review

The cell therapy REMaST, developed by Hemera for the regeneration of nervous tissue in spinal cord injuries, was the focus of a dedicated report on TG3 Leonardo, the Italian public broadcaster’s science and technology program. The segment highlighted the innovative...

Hemera announces the publication in Immunity of preclinical discoveries on REMaST® for neural tissue regeneration

Jan 26, 2026 | News, Press Releases

A peer-reviewed study demonstrates the therapeutic potential of REMaST® in spinal cord repair and neuronal regeneration Hemera is pleased to announce the online preprint publication of the manuscript “Tumor-associated macrophages enhance peripheral nerve tumor...

Published in STAR Protocols: Severe contusive preclinical model confirms the preclinical value of REMaST®

Dec 28, 2025 | News

Researchers at Hemera, including co-founders Ilaria Decimo and Francesco Bifari and senior scientist Sissi Dolci, have published a key study in STAR Protocols by Cell Press, essential for the development of REMaST®, our advanced cell therapy for nervous tissue...